Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report
Cytomegalovirus (CMV) infection in patients with hematologic malignancies who have not undergone stem cell transplantation remains poorly understood. Reports of clinically significant CMV infections in patients receiving Bruton Tyrosine Kinase inhibitors (BTKi) are rare. We present a case of ganciclovir-resistant CMV encephalitis in a patient with mantle cell lymphoma (MCL) treated with pirtobrutinib (a third generation BTKi). This case highlights the importance of maintaining a high index of suspicion for CMV infection in patients with hematologic malignancies, including those receiving therapies traditionally considered to carry a lower risk of opportunistic infections.
Authors
- Steven M. Bair (ORCID: https://orcid.org/0000-0002-0094-0014)
- Rebecca Unterborn (ORCID: https://orcid.org/0000-0003-2091-5905)
- Karrine Brade (ORCID: https://orcid.org/0000-0001-7905-2417)
- Chia‐Yu Chiu (ORCID: https://orcid.org/0000-0002-5241-3435)
Institutions
- University of Colorado Hospital (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- IDCases
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.idcr.2025.e02396
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00